Regulatory decisions pertaining to aprotinin may be putting patients at risk

CMAJ

Volumn 186, Issue 18, 2014, Pages 1379-1386

  Hébert, Paul C ^a,b   Fergusson, Dean A ^c,d   Hutton, Brian ^d   Mazer, C David ^d   Fremes, Stephen ^e   Blajchman, Morris ^f   MacAdams, Charles ^g   Wells, George ^h   Robblee, Jim ⁱ   Bussières, Jean ^j   Teoh, Kevin ^g  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^j LAVAL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; HEPARIN; KAOLIN; LYSINE DERIVATIVE; PLACEBO; TRANEXAMIC ACID;

ANTICOAGULATION; ARTICLE; BLEEDING; CANADA; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DEATH; DRUG APPROVAL; DRUG CONTROL; DRUG FATALITY; DRUG SAFETY; DRUG USE; HEART SURGERY; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MEDICAL DECISION MAKING; RANDOMIZATION; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); LEGISLATION AND JURISPRUDENCE; RISK;

ANTIFIBRINOLYTIC AGENTS; APROTININ; CANADA; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; RISK;

EID: 84918815142     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.131582     Document Type: Article

References (27)

1. FDA requests marketing suspension of Trasylol [press release]. Silver Spring (MD): US Food and Drug Administration; 2007 Nov. 5. Available: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109021.htm. (accessed 2012 July 9).
2. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-67.
3. Carless PA, Moxey AJ, Stokes BJ, et al. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord 2005;5:19.
4. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-8.
5. Fergusson D, Glass KC, Hutton B, et al. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding? Clin Trials 2005;2:218-29.
6. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31.
7. DeAnda A, Spiess BD. Aprotinin revisited. J Thorac Cardiovasc Surg. 2012;144:998-1002.
8. Tempe DK, Hasija S. Are tranexamic acid and eaminocaproic acid adequate substitutes for aprotinin? Ann Card Anaesth 2012; 15:4.
9. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 1940-7.
10. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8.
11. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008;358:784-93.
12. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83.
13. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
14. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-9.
15. FDA issues public health advisory for Trasylol [press release]. Silver Spring (MD): US Food and Drug Administration; 2006 Feb. 8. Available: www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108592.htm. (accessed 2014 Sept. 2).
16. Signal Assessment: Trasylol (aprotinin) and mortality in the BART study. Ottawa: Health Canada; 2010.
17. Health Canada decision on Trasylol (aprotinin). Ottawa: Health Canada; 2011. Available: www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2011/2011-124-eng.php (accessed 2012 July 10).
18. European Medicines Agency recommends lifting suspension of aprotinin [press release]. European Medicines Agency; 2012 Nov. 17. Available: www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2012/02/news-detail-001447.jsp&mid=WC0b01ac058004d5c1 (accessed 2012 July 9).
19. Expert Advisory Panel for Trasylol (aprotinin). Ottawa: Health Canada; 2009. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advise-consult/eap-gce-trasylol/final-rep-rap-eng.php (accessed 2012 July 11).
20. Canadian Pharmacists Association. Trasylol. In: Canadian Pharmacists Association, editor. Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association; 2012: 2710-2.
21. Fergusson D, Aaron SD, Guyatt G, et al. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002;325:652-4.
22. Michaud D, Fergusson DA, MacAdams C, et al. Assessment of bleeding in a randomized controlled trial comparing antifibrinolytics. Anesth Analg 2007;104:SCA72.
23. Despotis GJ, Filos KS, Levine V, et al. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg 1996; 82: 1126-31.
24. Tanaka KA, Szlam F, Katori N, et al. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res 2004;113:333-9.
25. Hutton B, Joseph L, Fergusson D, et al. Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies. BMJ 2012;345:e5798.
26. Brown JR. Mortality manifesto: a meta-analysis of aprotinin and tranexamic acid mortality. Eur J Cardiothorac Surg 2009; 36:781-2.
27. Takagi H, Manabe H, Kawai N, et al. Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials. Interact Cardiovasc Thorac Surg 2009;9:98-101.